US Q1 2020 EARNINGS SEASON IS NOT BAD, EXPECT NEGATIVE REVISIONS TO LINGER

Nearly 70% of the reporting season is out, while only 25% of companies have reported in Japan. As usual, US and EU, having more defensive sector mix, are more resilient vs. EMU during recessions. Japan isbehaving not too badly for the time being.

Highlights:

  • Two thirds of EU and US firms reported results. EU fared less well than the US. Beats are not so negative but yoy growth is -22% and -8%, respectively. The median stock result is better: -5% for EU and +1.7% for the US.
  • Q2 results will be much worse – bottom of the cycle in a base case scenario – but analysts expect growth in Q3 to remain lower vs Q1: there is still a long way to go for earnings’ downgrades.
  • Our earnings forecasts for 2020 and 2021 remain below consensus and have risks tilted on the downside.
  • Recovery uncertainties, a possible second wave of contagion, geopolitical frictions plus lack of unity in the euro area do not bode well for earnings revisions in the next months.
  • Concerning sector earnings growth (yoy), consumer services, pharma, staples, IT and utilities were better than discretionary, energy, financials and industrials. 
  • At the EM market level, the most export-oriented EM countries (Korean, Taiwan), which fared well through the COVID crisis, have disappointed the least. They have shown twice as high the ratio of positive to total surprises (65%) vs other EM markets covered (Brazil, China, India) but Q2 would be a more severe test.
  • Overall, we maintain an OW on equities, having reduced it significantly after the rally.
  • While market valuation looks stretched short term, we see positive total returns over one year, even incorporating huge earnings downside in 2020 and lower earnings recovery in 2021 compared to previous post-recession periods.

Download the full publication belo

US Q1 2020 EARNINGS SEASON IS NOT BAD, EXPECT NEGATIVE REVISIONS TO LINGER

RELATED INSIGHTS

COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.
INCORPORATING QUANT SIGNALS INTO EU EQUITY SECTOR/STYLE STRATEGY: MAINTAIN A TILT TO CYCLICALS AND VALUE
We present an update of our proprietary equity valuation tool, based on quant models. It provides indications of over- or undervaluation for different sectors and styles of European equities, which is further enriched by our qualitative analysis. Currently, among European equity sectors, financials, energy, telecoms, and autos look undervalued while Pharma, utilities and software appear overvalued.
CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.